Belzutifan
- Generic Name
- Belzutifan
- Brand Names
- Welireg, 维利瑞
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12F3NO4S
- CAS Number
- 1672668-24-4
- Unique Ingredient Identifier
- 7K28NB895L
- Background
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable, a binding pocket was eve...
- Indication
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.
- Associated Conditions
- Hemangioblastoma, Pancreatic Neuroendocrine Cancer, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 50
- Registration Number
- NCT03401788
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2022-09-19
- Target Recruit Count
- 120
- Registration Number
- NCT02974738
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.